Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonaprisan in metastatic breast cancer
NCT00555919Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2008
- Primary completion
- Apr 2010
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of lonaprisan in breast cancer (2 arms), sponsored by Bayer. Primary endpoint: Clinical Benefit Rate at 6 months. Started Mar 2008; status: completed.
02
Drugs
lonaprisan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00555919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555919.